Population exposure–response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma
Authors:
Open Access
- 17 April 2018
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 81 (6) , 1061-1070
Abstract
In the phase III METEOR trial, tyrosine kinase inhibitor cabozantinib significantly improved progression-free survival (PFS), objective response rate (ORR), and overall survival compared to everolimus in patients with advanced renal cell carcinoma (RCC) who had received prior VEGFR inhibitor therapy. In METEOR, RCC patients started at a daily 60-mg cabozantinib tablet (Cabometyx™) dose but could reduce to 40- or 20-mg to achieve a tolerated exposure.Keywords
This publication has 16 references indexed in Scilit:
- Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted TherapyEuropean Urology, 2016
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2015
- Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major MetabolitesDrug Metabolism and Disposition, 2015
- Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response AnalysisClinical Pharmacokinetics, 2015
- Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and METProceedings of the National Academy of Sciences, 2014
- A Review of Mixed‐Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population AnalysisCPT: Pharmacometrics & Systems Pharmacology, 2014
- Cancer treatment and survivorship statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor GrowthMolecular Cancer Therapeutics, 2011
- Kinase requirements in human cells: III. Altered kinase requirements inVHL−/− cancer cells detected in a pilot synthetic lethal screenProceedings of the National Academy of Sciences, 2008
- Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature reviewCancer Treatment Reviews, 2008